Trademark Overview
On Tuesday, December 13, 2022, a trademark application was filed for PAD-LOCK with the United States Patent and Trademark Office. The USPTO has given the PAD-LOCK trademark a serial number of 97716190. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, January 9, 2024. This trademark is owned by Enlaza Therapeutics, Inc.. The PAD-LOCK trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical products, preparations, and substances for the treatment of cancer; cancer therapeutics, namely, anti-cancer preparations; novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors; biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer; pharmaceutical products consisting of covalent protein biologics; pharmaceutical products, namely, covalent protein drugs; pharmaceuticals products consisting of synthetic biology enabled covalent protein biologics; pharmaceutical products consisting of covalent protein drugs; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
Chemical products for use in industry and science; reagents for use in scientific apparatus for chemical or biological analysis; reagents for medical research; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; enzymes for scientific use; cell culture media for use in scientific research; active chemical ingredients for use in the manufacture of anti-cancer drugs; laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors; antibodies for research use
Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs; research and development for the purpose of selective covalent modification of proteins; research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors; conducting clinical trials for others in the field of cancer therapeutics; biotechnology testing services, namely, synthetic chemistry,...
